Treatment and prevention of neurodegenerative diseases using gene therapy

Abstract

Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes.

1 .- 230 . (canceled) 
     
     
         231 . A method of treating or ameliorating Alzheimer's disease in a mammal, comprising administering to said mammal in vivo, by electroporation, a composition including one or more nucleic acids that induce a cellular immune response; wherein said one or more nucleic acids encode one or more cytokines selected from the group consisting of interleukin-4 (IL-4), interleukin-10 (IL-10), and transforming growth factor-β (TGF-β), and wherein said one or more nucleic acids are vectors and each vector comprises a promoter operably linked to a sequence encoding said cytokine. 
     
     
         232 . A method of treating or ameliorating Alzheimer's disease in a mammal, comprising administering to said mammal in vivo, by electroporation, a composition comprising:
 (i) one or more nucleic acids that induce a cellular immune response, wherein said one or more nucleic acids encode one or more cytokines selected from the group consisting of IL-4, IL-10 and TGF-β; and   (ii) one or more nucleic acids selected from the group consisting of nucleic acids encoding apolipoprotein E-2 (ApoE-2), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF),   
       wherein said one or more nucleic acids are vectors and each vector comprises a promoter operably linked to a sequence encoding said cytokine, ApoE-2, NGF, or BDNF. 
     
     
         233 . The method of  claim 231 , wherein said composition comprises two or more nucleic acids encoding two or more cytokines selected from the group consisting of IL-4, IL-10, and TGF-β. 
     
     
         234 . The method of  claim 231 , wherein said mammal is a human. 
     
     
         235 . The method of  claim 231 , wherein said promoter is suitable for expression in eukaryotic cells. 
     
     
         236 . The method of  claim 231 , wherein said vector is selected from the group consisting of pVAXI, pUMCV, pGCy, and pLentilox-IRES-GFP. 
     
     
         237 . The method of  claim 234 , wherein said administration results in the decrease of amyloid plaque accumulation in the brain of said human in comparison to said human before said administration. 
     
     
         238 . A method of decreasing the level of amyloid proteins in the brain of a mammal, comprising administering to said mammal in vivo, by electroporation, a composition comprising one or more nucleic acids that induce a cellular immune response;
 wherein said one or more nucleic acids encode one or more cytokines selected from the group consisting of IL-4, IL-10, and TGF-β, and   wherein said one or more nucleic acids are vectors and each vector comprises a promoter operably linked to a sequence encoding said cytokine.   
     
     
         239 . A method of treating or ameliorating Alzheimer's disease in a mammal, comprising administering to said mammal in vivo, by electroporation, a composition comprising one or more nucleic acids that induce a cellular immune response, wherein:
 (i) said one or more nucleic acids encode one or more cytokines selected from the group consisting of IL-4, IL-10, and TGF-β;   (ii) said one or more nucleic acids are vectors and each vector comprises a promoter operably linked to a sequence encoding said cytokine; and   (iii) said composition does not comprise β-amyloid or β-amyloid 1-42 .   
     
     
         240 . The method of  claim 239 , wherein said composition further comprises one or more nucleic acids selected from the group consisting of nucleic acids encoding ApoE-2, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF).